A universal enabling solution to support bone repair
Tegenix and TegenEOS
These are the first products developed utilising the Tetramatrix™ platform technology, as an innovative carrier designed to be mixed with a broad array of bone graft materials (BGMs) for dental, oral and orthopaedic applications. The products are delivered via syringe and form a matrix as they reach the patient’s body temperature, providing a stable base for BGMs while they integrate with host tissues.
Demonstrates efficacy and safety in clinical studies1,2
Modular, Flexible and Flowable Formulations
A carrier system for the delivery of bone graft materials (BGMs), including synthetic, animal or human derived products. The modularity of our carrier system allows composite formulations in multiple forms, including flowable putties. The BGM content in the composites can range from 30% to 80%, addressing different clinical needs and market demands. The resulting composites can be delivered directly into a defect site, either via direct injection or gentle press-fit, simplifying a range of clinical usage with BGM.
Geometrically Stabilising Bone Graft at the Anatomical Sites
The carrier system retains BGM particles in place three-dimensionally, allowing cellular ingrowth within the carrier structure and the composite. As such, the activation of the particles is optimised and the composites do not structurally collapse. This allows better and more advanced integration and activation of the BGM. In a pre-clinical osteoinduction model, the composites formed with 70% active demineralised bone matrix (DBM) and 30% carrier displayed a higher degree of osteoinductivity compared to 100% DBM.
Allowing Uniform Trabecular Bone Ingrowth
The biomimetic nature of the derivatives on the Tetramatrix™ platform technology and its biocompatible properties allow cellular ingrowth and integration of the host bone tissue within the implant. In a clinical trial, products derived from the Tetramatrix™ platform technology were mixed with BGM and implanted in a dental socket site. Histological evaluations of the implantation sites 5 months post op showed trabecular bone ingrowth within the sites filled with the Tetramatrix™ platform technology derivatives with minimal inflammatory response to our carrier. However in the control group, patients treated with a commercially available product, used for bone regeneration, sites were filled with fibrovascular inflammatory tissues.
Soft and Hard Tissue Healing that provides a path for faster recovery
Products derived from the Tetramatrix™ platform technology support soft tissue healing and uniform bone repair. The results from a clinical study showed that the soft tissue healing and wound closure is achieved in a shorter period of time in patients treated with the product derived from the Tetramatrix™ platform technology compared with the current standard of care. CT-scans of the sites also showed that the use of products derived from Tetramatrix™ platform technology allows uniform hard tissue ingrowth and minimises bone loss at the treatment sites. These results demonstrate that the recovery time might be reduced by using carrier systems, derived from the Tetramatrix™ platform technology.